BTLA is an immune checkpoint receptor primarily expressed on T and B lymphocytes. By binding to its ligand HVEM, BTLA transmits an inhibitory signal that dampens lymphocyte activation and proliferation, functioning as a natural brake on the immune system. In the tumor microenvironment, this pathway can suppress anti-tumor immunity, making BTLA a strategic target for cancer immunotherapy.